PATENT CLAIM ANALYSIS

Application Number: 16142691
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "312000"]

Abstract:
This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.

Claim (Index 6):
The method of  claim 5 , wherein Compound 1 is the (L)- or (D)-malate salt.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 97.0
- Lexical Diversity: 1.08
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14398188', '14346570', '15348716', '14681974', '14353251']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7511822099894843
- 35 USC 102 Novelty (BERT): 0.4959752688606943
- Combined Prediction Score: 0.7256615158766053
- Mean Citation Score: 190.990714
- Max Citation Score: 205.31714
- Similarity Product: 139.2767537445998

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test